Biodexa Pharmaceuticals (BDRX) Long-Term Debt Repayments (2013 - 2016)

Biodexa Pharmaceuticals (BDRX) has 4 years of Long-Term Debt Repayments data on file, last reported at -$292157.2 in Q4 2016.

• For the quarter ending Q4 2016, Long-Term Debt Repayments fell 16.68% year-over-year to -$292157.2; the trailing twelve-month figure through Dec 2016 stood at -$1.4 million (changed N/A YoY), and the FY2019 full-year result was -$736735.6, up 90.52% from the prior year.
• Long-Term Debt Repayments slipped to -$292157.2 in Q4 2016, from -$250385.9 in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of -$250385.9 in Q4 2015 to a low of -$548203.5 in Q4 2014.
• A 4-year average of -$353640.3 and a median of -$307985.9 in 2013 frame the typical range for Long-Term Debt Repayments.
• Across the five-year window, Long-Term Debt Repayments sank 69.3% in 2014 and surged 54.33% in 2015, its largest moves.
• Tracing BDRX's Long-Term Debt Repayments over 4 years: stood at -$323814.7 in 2013, then plunged by 69.3% to -$548203.5 in 2014, then soared by 54.33% to -$250385.9 in 2015, then dropped by 16.68% to -$292157.2 in 2016.
• Business Quant data shows BDRX's Long-Term Debt Repayments at -$292157.2 in Q4 2016, -$250385.9 in Q4 2015, and -$548203.5 in Q4 2014.